BACKGROUND Checkpoint inhibitor–associated autoimmune diabetes mellitus (CIADM) is
a distinct form of autoimmune diabetes that is a rare complication of immune checkpoint …

Immune checkpoint inhibitor therapies act through blockade of inhibitory molecules involved
in the regulation of T cells, thus releasing tumor specific T cells to destroy their tumor targets …

The immune response in cancer reflects a series of carefully regulated events; however,
current tumor immunotherapies typically address a single key aspect to enhance anti‐tumor …

Immune checkpoint inhibitors (ICIs) reinvigorate anti-tumor immune responses by disrupting
co-inhibitory immune checkpoint molecules such as programmed cell death 1 (PD-1) and …

With the increasing use of immune-checkpoint inhibitors (ICIs), such as anti-cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) and anti-programmed cell death-1 (PD-1), for the …

Cancer patients treated with immune checkpoint inhibitors (ICIs) are susceptible to a broad
and variable array of immune‐related adverse events (irAEs). With increasing clinical use of …

Background Immune checkpoint inhibitors (ICIs) have dramatically improved survival in
patients with cancer but are often accompanied by severe immune-related adverse events …

Single cell genomics has revolutionized our ability to map immune heterogeneity and
responses. With the influx of large-scale data sets from diverse modalities, the resolution …

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer
treatment and more patients are receiving ICIs than before. Although this has improved …

Oxidative stress and inflammation caused by cisplatin, which is frequently used in the
treatment of many cancers, damage healthy tissues as well as cancer cells. In this study, we …